Clin Chem:偶尔和长期吸食大麻者模拟驾驶对警惕性和事故风险的影响及其药代动力学-药效学关系

2019-07-21 不详 MedSci原创

目前,有关全血δ<span lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:14.0pt;font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;; mso-fareast-font-family:宋体;mso-bidi-font-family:&quot;Times New Ro

目前,有关全血δ-9-四氢大麻酚(THC)与驱动风险之间的药代动力学 - 药效学关系知之甚少。

本研究包括年龄1834岁的15例慢性大麻使用者(每天1-2;CC)15名偶尔吸食大麻者(每周1-2;OC)。在控制随机吸入安慰剂或10mg30mg THC之前和之后的24小时内进行12血液采样的药代动力学研究。通过精神运动警戒测试和通过约克驾驶模拟器的驾驶性能对反应时间的影响对参与者评估7次。使用LC-MS / MS定量THC和代谢物。采用R软件进行药代动力学-药效学分析。

研究显示,在相同剂量下,CC组全血THC峰值是OC组的2倍,且发生在用药结束后5分钟。THC只有在24小时后才能在CC中检测到。反应时间的最大影响是剂量和分组,而对于驾车表现只有分组因素影响,在OC组中,下降更明显。这些作用在给药后5小时左右达到最大,OC组持续时间较CC组长。研究仅在血液THCTmax和对平均倒数反应时间的持续时间影响之间观察到显著的药代动力学 - 药效学关系。

研究表明,大麻吸入导致血液THC快速增加,警惕性和驾驶性能延迟下降,OCCC更明显,持续时间更长。

原始出处:

Sarah Hartley, Nicolas Simon,Effect of Smoked Cannabis on Vigilance and Accident Risk Using Simulated Driving in Occasional and Chronic Users and the PharmacokineticPharmacodynamic Relationship

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1933256, encodeId=93da19332563c, content=<a href='/topic/show?id=1bdd3945300' target=_blank style='color:#2F92EE;'>#吸食大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39453, encryptionId=1bdd3945300, topicName=吸食大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af68384, createdName=hanhaisha2008, createdTime=Wed Jan 15 14:31:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666734, encodeId=bb891666e34ba, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Nov 19 02:31:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672319, encodeId=4abe16e23197f, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Fri May 01 09:31:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718900, encodeId=c1d81e18900d9, content=<a href='/topic/show?id=cf168e59360' target=_blank style='color:#2F92EE;'>#药效学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87593, encryptionId=cf168e59360, topicName=药效学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4c132663291, createdName=liuhuangbo, createdTime=Sun Nov 03 07:31:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272742, encodeId=868212e2742f9, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Jul 23 11:31:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351274, encodeId=3e3413512e488, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 23 11:31:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370081, encodeId=29c33e008125, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Jul 22 06:47:59 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1933256, encodeId=93da19332563c, content=<a href='/topic/show?id=1bdd3945300' target=_blank style='color:#2F92EE;'>#吸食大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39453, encryptionId=1bdd3945300, topicName=吸食大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af68384, createdName=hanhaisha2008, createdTime=Wed Jan 15 14:31:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666734, encodeId=bb891666e34ba, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Nov 19 02:31:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672319, encodeId=4abe16e23197f, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Fri May 01 09:31:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718900, encodeId=c1d81e18900d9, content=<a href='/topic/show?id=cf168e59360' target=_blank style='color:#2F92EE;'>#药效学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87593, encryptionId=cf168e59360, topicName=药效学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4c132663291, createdName=liuhuangbo, createdTime=Sun Nov 03 07:31:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272742, encodeId=868212e2742f9, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Jul 23 11:31:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351274, encodeId=3e3413512e488, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 23 11:31:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370081, encodeId=29c33e008125, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Jul 22 06:47:59 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
    2019-11-19 fengyqf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1933256, encodeId=93da19332563c, content=<a href='/topic/show?id=1bdd3945300' target=_blank style='color:#2F92EE;'>#吸食大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39453, encryptionId=1bdd3945300, topicName=吸食大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af68384, createdName=hanhaisha2008, createdTime=Wed Jan 15 14:31:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666734, encodeId=bb891666e34ba, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Nov 19 02:31:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672319, encodeId=4abe16e23197f, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Fri May 01 09:31:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718900, encodeId=c1d81e18900d9, content=<a href='/topic/show?id=cf168e59360' target=_blank style='color:#2F92EE;'>#药效学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87593, encryptionId=cf168e59360, topicName=药效学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4c132663291, createdName=liuhuangbo, createdTime=Sun Nov 03 07:31:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272742, encodeId=868212e2742f9, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Jul 23 11:31:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351274, encodeId=3e3413512e488, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 23 11:31:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370081, encodeId=29c33e008125, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Jul 22 06:47:59 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
    2020-05-01 lsndxfj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1933256, encodeId=93da19332563c, content=<a href='/topic/show?id=1bdd3945300' target=_blank style='color:#2F92EE;'>#吸食大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39453, encryptionId=1bdd3945300, topicName=吸食大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af68384, createdName=hanhaisha2008, createdTime=Wed Jan 15 14:31:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666734, encodeId=bb891666e34ba, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Nov 19 02:31:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672319, encodeId=4abe16e23197f, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Fri May 01 09:31:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718900, encodeId=c1d81e18900d9, content=<a href='/topic/show?id=cf168e59360' target=_blank style='color:#2F92EE;'>#药效学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87593, encryptionId=cf168e59360, topicName=药效学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4c132663291, createdName=liuhuangbo, createdTime=Sun Nov 03 07:31:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272742, encodeId=868212e2742f9, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Jul 23 11:31:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351274, encodeId=3e3413512e488, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 23 11:31:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370081, encodeId=29c33e008125, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Jul 22 06:47:59 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1933256, encodeId=93da19332563c, content=<a href='/topic/show?id=1bdd3945300' target=_blank style='color:#2F92EE;'>#吸食大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39453, encryptionId=1bdd3945300, topicName=吸食大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af68384, createdName=hanhaisha2008, createdTime=Wed Jan 15 14:31:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666734, encodeId=bb891666e34ba, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Nov 19 02:31:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672319, encodeId=4abe16e23197f, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Fri May 01 09:31:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718900, encodeId=c1d81e18900d9, content=<a href='/topic/show?id=cf168e59360' target=_blank style='color:#2F92EE;'>#药效学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87593, encryptionId=cf168e59360, topicName=药效学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4c132663291, createdName=liuhuangbo, createdTime=Sun Nov 03 07:31:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272742, encodeId=868212e2742f9, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Jul 23 11:31:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351274, encodeId=3e3413512e488, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 23 11:31:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370081, encodeId=29c33e008125, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Jul 22 06:47:59 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
    2019-07-23 kcb069
  6. [GetPortalCommentsPageByObjectIdResponse(id=1933256, encodeId=93da19332563c, content=<a href='/topic/show?id=1bdd3945300' target=_blank style='color:#2F92EE;'>#吸食大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39453, encryptionId=1bdd3945300, topicName=吸食大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af68384, createdName=hanhaisha2008, createdTime=Wed Jan 15 14:31:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666734, encodeId=bb891666e34ba, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Nov 19 02:31:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672319, encodeId=4abe16e23197f, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Fri May 01 09:31:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718900, encodeId=c1d81e18900d9, content=<a href='/topic/show?id=cf168e59360' target=_blank style='color:#2F92EE;'>#药效学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87593, encryptionId=cf168e59360, topicName=药效学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4c132663291, createdName=liuhuangbo, createdTime=Sun Nov 03 07:31:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272742, encodeId=868212e2742f9, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Jul 23 11:31:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351274, encodeId=3e3413512e488, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 23 11:31:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370081, encodeId=29c33e008125, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Jul 22 06:47:59 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1933256, encodeId=93da19332563c, content=<a href='/topic/show?id=1bdd3945300' target=_blank style='color:#2F92EE;'>#吸食大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39453, encryptionId=1bdd3945300, topicName=吸食大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af68384, createdName=hanhaisha2008, createdTime=Wed Jan 15 14:31:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666734, encodeId=bb891666e34ba, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Nov 19 02:31:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672319, encodeId=4abe16e23197f, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Fri May 01 09:31:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718900, encodeId=c1d81e18900d9, content=<a href='/topic/show?id=cf168e59360' target=_blank style='color:#2F92EE;'>#药效学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87593, encryptionId=cf168e59360, topicName=药效学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4c132663291, createdName=liuhuangbo, createdTime=Sun Nov 03 07:31:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272742, encodeId=868212e2742f9, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Jul 23 11:31:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351274, encodeId=3e3413512e488, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 23 11:31:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370081, encodeId=29c33e008125, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Jul 22 06:47:59 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
    2019-07-22 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

新的临床证据表明短肠综合征药物(SBS)glepaglutide具有长效潜力

近日,Zealand制药公布了其旗下的长效人胰高血糖素样多肽-1(GLP-1)类似物glepaglutide的药代动力学数据,支持了glepaglutide用以短肠综合征治疗的每周一次或两次的给药方案。在试验中,研究者评估了每日和每周的皮下注射的不同剂量,结果表明每周两次及每周一次的给药剂量已经显示出了足够的临床暴露效果。因此研究者们计划在未来的III期临床试验中招募120和150名患者分配到每周

Chest:四种静脉维生素C给药方案在危重症患者的药代动力学分析

由此可见,2g/d的治疗剂量与正常血浆浓度相关,10g/d的治疗剂量与正常偏高的血浆浓度、增加的草酸盐排泄和代谢性碱中毒相关。持续治疗需要预防维生素缺乏症。

抗菌药物药代动力学/药效学理论临床应用专家共识

在目前细菌耐药迅速变迁、新抗菌药物研发严重滞后的情况下,药代动力学/药效学(PK/PD)理论的临床应用是发挥现有抗菌药物治疗潜力的可靠策略之一,务必给予足够的重视。近年来关于抗菌药物PK/PD的研究进展迅速,研究发现重症感染患者与健康人的PK/PD数据明显不同,为此国外相关指南做出了相应修改感染性疾病的诊治需要多学科的协作,临床医师需要掌握足够的临床药理学知识指导临床治疗,但目前我国尚缺少完整统一

Ra Pharma宣布Zilucoplan在肾功能不全患者中的药代动力学结果

Ra Pharma近日公布了该公司的Ib期药代动力学(PK)研究的阳性结果,该研究评估了肾功能损伤患者使用zilucoplan(RA101495 SC)的药代动力学情况。

JAMA Pediatr:肥胖儿童用药剂量怎么确定?

 儿童肥胖的趋势已经稳定在一定的比例。在美国,几乎六分之一的儿童或青少年是肥胖的。这导致了身体组成和生理学的改变,这会影响到药物处置,可能导致治疗失败或者毒副作用。然而对于已有的与肥胖对药物安全、药物代谢动力学和肥胖儿童的用药剂量的深度探究仍是未知的。杜克大学的研究人员对此进行了一次系统性文献综述以描述当前掌握的儿童肥胖对于药物处置的影响的一些证据。 研究人员检索了MEDLIN

Invest New Drugs:dacomitinib(pan-HER 抑制剂)用于晚期头颈部鳞状细胞癌的药代动力学评价

背景:Dacomitinib是一种不可逆的口服pan-HER酪氨酸激酶抑制剂,其针对复发性/转移性(RM)头颈部鳞状细胞癌(SCCHN)有抗肿瘤活性的功效。Dacomitinib相比于标准治疗晚期头颈部鳞状细胞癌的I期临床试验正在进行中(NCT01737008)。许多头颈部鳞状细胞癌患者需要进行肠内喂养,本研究的目的是通过胃造口术喂食管给药时,dacomitinib的药代动力学PK性质(NCT01